FWIW I was doing some website searching, and came across about 10 or 20 new website names that Pfizer has purchased in the past 6 months or so...they paid some pretty big bucks for them too! Maybe they've got some plans for us in the near future - who knows!
>>VEGF also is the target of a Phase III macular degeneration product, Lucentis (ranibizumab), from South San Francisco-based Genentech Inc., but the Angiosyn compound works through a different pathway.<<
Too bad they aren’t saying what that other pathway is. “Competitive reasons,” no doubt.
Market Data 
Markets 
AI
